501 - 525 of 6568 Results
Title
Year
-
OPENTitle: ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 91Issue #:Start Page: 139End Page: 145Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.09.024Best OA location URL: http://www.prd-journal.com/article/S1353802021003539/pdfCitation Count: 50
-
OPENTitle: Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medicationsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 92Issue #:Start Page: 59End Page: 66Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.10.009Best OA location URL: http://www.prd-journal.com/article/S1353802021003643/pdfCitation Count: 57
-
OPENTitle: Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 96Issue #:Start Page: 38End Page: 42Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.017Best OA location URL: https://doi.org/10.1016/j.parkreldis.2022.01.017Citation Count: 32
-
OPENTitle: Stimulation of the pedunculopontine and cuneiform nuclei for freezing of gait and falls in Parkinson disease: Cross-over single-blinded study and long-term follow-upJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 96Issue #:Start Page: 13End Page: 17Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.010Best OA location URL: https://hal.sorbonne-universite.fr/hal-03603648Citation Count: 19
-
OPENTitle: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 133End Page: 137Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002Best OA location URL: http://www.prd-journal.com/article/S1353802020309007/pdfCitation Count: 7
-
OPENTitle: Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI databaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 34End Page: 37Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.007Best OA location URL: https://repositorio.uca.edu.ar/handle/123456789/11625Citation Count: 21
-
OPENTitle: Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 83Issue #:Start Page: 79End Page: 85Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.024Best OA location URL: http://www.prd-journal.com/article/S135380202100016X/pdfCitation Count: 84
-
OPENTitle: Exploratory analysis of the genetics of impulse control disorders in Parkinson's disease using genetic risk scoresJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 74End Page: 77Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.003Best OA location URL: https://hal.archives-ouvertes.fr/hal-03298502Citation Count: 11
-
OPENTitle: Consistent skin α-synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 108End Page: 113Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.007Best OA location URL: http://hdl.handle.net/11380/1251595Citation Count: 37
-
OPENTitle: Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patientsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 25End Page: 31Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.012Best OA location URL: http://www.prd-journal.com/article/S1353802021001450/pdfCitation Count: 22
- Plasma NfL, clinical subtypes and motor progression in Parkinson's disease2021OPENTitle: Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 41End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016Citation Count: 60
-
OPENTitle: Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse modelJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 218Issue #:Start Page: 109213End Page: 109213Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109213Best OA location URL: https://doi.org/10.1016/j.neuropharm.2022.109213Citation Count: 11
- Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways2021OPENTitle: Glucocerebrosidase mutations: A paradigm for neurodegeneration pathwaysJournal Name: Free Radical Biology and MedicinePublisher: Elsevier BVVol: 175Issue #:Start Page: 42End Page: 55Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.freeradbiomed.2021.08.230Citation Count: 23
-
OPENTitle: Comparison of manual and automated measures of walking speed: Distance and pace matterJournal Name: Experimental GerontologyPublisher: Elsevier BVVol: 170Issue #:Start Page: 111987End Page: 111987Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.exger.2022.111987Best OA location URL: https://doi.org/10.1016/j.exger.2022.111987Citation Count: 6
-
OPENTitle: Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned ratJournal Name: European Journal of PharmacologyPublisher: Elsevier BVVol: 929Issue #:Start Page: 175090End Page: 175090Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ejphar.2022.175090Best OA location URL: https://doi.org/10.1016/j.ejphar.2022.175090Citation Count: 19
-
OPENTitle: Emotions Modulate Subthalamic Nucleus Activity: New Evidence in Obsessive-Compulsive Disorder and Parkinson’s Disease PatientsJournal Name: Biological Psychiatry: Cognitive Neuroscience and NeuroimagingPublisher: Elsevier BVVol: 6Issue #: 5Start Page: 556End Page: 567Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bpsc.2020.08.002Best OA location URL: https://www.sciencedirect.com/science/article/am/pii/S2451902220302123?via%3DihubCitation Count: 18
-
OPENTitle: Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: A randomized controlled trialJournal Name: Brain StimulationPublisher: Elsevier BVVol: 15Issue #: 3Start Page: 857End Page: 860Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.brs.2022.05.012Best OA location URL: http://www.brainstimjrnl.com/article/S1935861X22000912/pdfCitation Count: 24
-
OPENTitle: Analysis of voice as an assisting tool for detection of Parkinson's disease and its subsequent clinical interpretationJournal Name: Biomedical Signal Processing and ControlPublisher: Elsevier BVVol: 66Issue #:Start Page: 102415End Page: 102415Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.bspc.2021.102415Best OA location URL: https://doi.org/10.1016/j.bspc.2021.102415Citation Count: 65
-
OPENTitle: Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 203End Page: 212Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30449-xBest OA location URL: http://hdl.handle.net/2445/214932Citation Count: 331
-
OPENTitle: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 182End Page: 192Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30489-0Best OA location URL: http://www.thelancet.com/article/S1474442220304890/pdfCitation Count: 137
-
OPENTitle: Prehospital scales in acute ischaemic stroke management – Authors' replyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 504End Page: 505Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00169-1Best OA location URL: https://pure.eur.nl/en/publications/25abb6f2-0472-4754-8580-97e2533ac37aCitation Count: 1
-
OPENTitle: A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson’s diseaseJournal Name: Expert Opinion on Drug DeliveryPublisher: Informa UK LimitedVol: 18Issue #: 11Start Page: 1559End Page: 1569Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1080/17425247.2021.1960820Best OA location URL: https://www.tandfonline.com/doi/pdf/10.1080/17425247.2021.1960820?needAccess=trueCitation Count: 20
-
OPENTitle: The impact of COVID-19 on palliative care for people with Parkinson’s and response to future pandemicsJournal Name: Expert Review of NeurotherapeuticsPublisher: Informa UK LimitedVol: 21Issue #: 6Start Page: 615End Page: 623Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1080/14737175.2021.1923480Best OA location URL: http://hdl.handle.net/11577/3395097Citation Count: 16
-
OPENTitle: Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosisJournal Name: Expert Review of ProteomicsPublisher: Informa UK LimitedVol: 18Issue #: 11Start Page: 977End Page: 994Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/14789450.2021.2004890Best OA location URL: https://www.tandfonline.com/doi/pdf/10.1080/14789450.2021.2004890?needAccess=trueCitation Count: 8
-
OPENTitle: Real-world assessment of “OFF” episode–related healthcare resource utilization among patients with Parkinson’s disease in the United StatesJournal Name: Journal of Medical EconomicsPublisher: Informa UK LimitedVol: 24Issue #: 1Start Page: 540End Page: 549Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1080/13696998.2021.1913009Best OA location URL: https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1913009?needAccess=trueCitation Count: 9